NCT03459222 2026-04-06
An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread
Bristol-Myers Squibb
Phase 1/2 Completed
Bristol-Myers Squibb
Bristol-Myers Squibb
Bristol-Myers Squibb
Bristol-Myers Squibb
Dana-Farber Cancer Institute
NYU Langone Health
Eli Lilly and Company
Bristol-Myers Squibb
Bristol-Myers Squibb
Bristol-Myers Squibb
BeiGene
Daiichi Sankyo
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company
Pfizer
Eli Lilly and Company
Merck Sharp & Dohme LLC
University of Saskatchewan